All news

Price target raised on Eli Lilly as obesity-drug boom rolls on

CNBC · RSS · · AI-summarised by FinFlash

Eli Lilly's price target has been raised, with analysts pointing to continued momentum in Mounjaro and Zepbound and further growth expected ahead. The call reflects sustained demand across the company's obesity and diabetes franchises. For investors, the upgrade signals confidence that Lilly's earnings trajectory can keep expanding rather than plateauing.

Read original source

LLY company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.